Sofosbuvir / Velpatasvir

DRUG2 trials

Sponsors

Atea Pharmaceuticals Inc., Peking University First Hospital

Conditions

Chronic Hepatitis BChronic Hepatitis CChronic Hepatitis C Virus (HCV) Infection

Phase 3

An Evaluation of Bemnifosbuvir-Ruzasvir (BEM/RZR) Versus Sofosbuvir-Velpatasvir (SOF/VEL) for the Treatment of Chronic Hepatitis C Virus (HCV) Infection in a Phase 3 Randomized, Controlled, Open-label Study

RecruitingCTIS2025-521096-31-00

Atea Pharmaceuticals Inc.Chronic Hepatitis C Virus (HCV) Infection

Start: 2025-10-02Target: 275Updated: 2026-01-21

Phase 4

The Efficacy and Safety of 12-week SOF/VEL Regimen Combined With Prophylactic Use of TAF for Treatment-naïve Genotype 1-6 HCV/HBV Co-infection Adult Patients With or Without Compensated Cirrhosis in China

Peking University First HospitalChronic Hepatitis B, Chronic Hepatitis C

Start: 2021-08-31End: 2023-12-31Target: 120Updated: 2021-08-09